Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

Where 2020 saw the development and testing of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has seen vaccine rollout in many countries. In this Progress article, we provide a snapshot of ongoing vaccine efficacy studies...

Full description

Saved in:

Bibliographic Details
Published in	Nature reviews. Immunology Vol. 21; no. 10; pp. 626 - 636
Main Authors	Tregoning, John S., Flight, Katie E., Higham, Sophie L., Wang, Ziyin, Pierce, Benjamin F.
Format	Journal Article
Language	English
Published	London Nature Publishing Group UK 01.10.2021 Nature Publishing Group
Subjects	631/250/590 631/326/596/4130 Adverse and side effects Biomedical and Life Sciences Biomedicine Clinical Trials as Topic Control Coronaviruses COVID-19 COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - adverse effects COVID-19 Vaccines - classification COVID-19 Vaccines - immunology Drugs Epidemics Health Services Accessibility Humans Immunology Medical research Medicine, Experimental Pandemics Progress SARS-CoV-2 - classification SARS-CoV-2 - genetics SARS-CoV-2 - immunology Severe acute respiratory syndrome coronavirus 2 United Kingdom Vaccine efficacy Vaccines Viruses World Health Organization United Kingdom
Online Access	Get full text

Cover

Loading…

Abstract	Where 2020 saw the development and testing of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has seen vaccine rollout in many countries. In this Progress article, we provide a snapshot of ongoing vaccine efficacy studies, as well as real-world data on vaccine effectiveness and the impact of virus variants of concern. Where they have been deployed in a high proportion of the adult population, the currently approved vaccines have been extremely effective in preventing COVID-19, particularly severe disease. Nonetheless, there are still significant challenges in ensuring equitable vaccine access around the globe and lessons that can be learned for controlling this pandemic and for the next pandemic. This Progress article provides an update on the COVID-19 vaccine effort in the light of ongoing vaccine efficacy studies and real-world data on vaccine effectiveness, including the impact of virus variants of concern and challenges for global deployment.
AbstractList	Where 2020 saw the development and testing of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has seen vaccine rollout in many countries. In this Progress article, we provide a snapshot of ongoing vaccine efficacy studies, as well as real-world data on vaccine effectiveness and the impact of virus variants of concern. Where they have been deployed in a high proportion of the adult population, the currently approved vaccines have been extremely effective in preventing COVID-19, particularly severe disease. Nonetheless, there are still significant challenges in ensuring equitable vaccine access around the globe and lessons that can be learned for controlling this pandemic and for the next pandemic. This Progress article provides an update on the COVID-19 vaccine effort in the light of ongoing vaccine efficacy studies and real-world data on vaccine effectiveness, including the impact of virus variants of concern and challenges for global deployment. Where 2020 saw the development and testing of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has seen vaccine rollout in many countries. In this Progress article, we provide a snapshot of ongoing vaccine efficacy studies, as well as real-world data on vaccine effectiveness and the impact of virus variants of concern. Where they have been deployed in a high proportion of the adult population, the currently approved vaccines have been extremely effective in preventing COVID-19, particularly severe disease. Nonetheless, there are still significant challenges in ensuring equitable vaccine access around the globe and lessons that can be learned for controlling this pandemic and for the next pandemic. This Progress article provides an update on the COVID-19 vaccine effort in the light of ongoing vaccine efficacy studies and real-world data on vaccine effectiveness, including the impact of virus variants of concern and challenges for global deployment. Where 2020 saw the development and testing of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has seen vaccine rollout in many countries. In this Progress article, we provide a snapshot of ongoing vaccine efficacy studies, as well as real-world data on vaccine effectiveness and the impact of virus variants of concern. Where they have been deployed in a high proportion of the adult population, the currently approved vaccines have been extremely effective in preventing COVID-19, particularly severe disease. Nonetheless, there are still significant challenges in ensuring equitable vaccine access around the globe and lessons that can be learned for controlling this pandemic and for the next pandemic.
Audience	Academic
Author	Pierce, Benjamin F. Wang, Ziyin Tregoning, John S. Flight, Katie E. Higham, Sophie L.
Author_xml	– sequence: 1 givenname: John S. orcidid: 0000-0001-8093-8741 surname: Tregoning fullname: Tregoning, John S. email: john.tregoning@imperial.ac.uk organization: Department of Infectious Disease, St Mary’s Campus, Imperial College London – sequence: 2 givenname: Katie E. surname: Flight fullname: Flight, Katie E. organization: Department of Infectious Disease, St Mary’s Campus, Imperial College London – sequence: 3 givenname: Sophie L. surname: Higham fullname: Higham, Sophie L. organization: Department of Infectious Disease, St Mary’s Campus, Imperial College London – sequence: 4 givenname: Ziyin orcidid: 0000-0002-1110-808X surname: Wang fullname: Wang, Ziyin organization: Department of Infectious Disease, St Mary’s Campus, Imperial College London – sequence: 5 givenname: Benjamin F. orcidid: 0000-0002-0834-5201 surname: Pierce fullname: Pierce, Benjamin F. organization: Department of Infectious Disease, St Mary’s Campus, Imperial College London
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/34373623$$D View this record in MEDLINE/PubMed
BookMark	eNp9kltr3DAQhU1JaS7tH-hDMRQKhTi1JFvS5qEQtreFQEpvr0KWx7sKXmmjkZfm31fuJpsYStGDRprvHMToHGcHzjvIspekPCMlk--wIrUQRUlJUZb1jBbkSXZEKlEVRFTkYF8zdpgdI16XJeGp8yw7ZBUTjFN2lN18DX4ZADH3XR5XkM-vfi0-FGSWb7Ux1kEOXedDPM-3NgwIeHrfwFy7Nh2C1S5ivoWAA460Ndrcno4VmGi34Eb3kQU0egPPs6ed7hFe3O0n2c9PH3_MvxSXV58X84vLwnBBY8EbXRkpgNKW1BwarnXbtaWsQZKW0LpsWt42nW5mbZfKupGUQ1UZWoEcT-wke7_z3QzNGloDLgbdq02wax1ulddWTTvOrtTSb5VkNaklSwav7wyCvxkAo7r2Q3DpzYrWggsmBKsfqKXuQVnX-WRm1haNuuCCS0kkrRJ19g8qrRbW1qRv7Wy6nwjeTgSJifA7LvWAqBbfv03ZN4_YFeg-rtD3Q7Te4RSkO9AEjxig20-DlGqMlNpFSqVIqb-RUiSJXj2e415yn6EEsB2AqeWWEB7m9B_bP50I188
CitedBy_id	crossref_primary_10_1038_s41392_022_01039_2 crossref_primary_10_3390_encyclopedia1040081 crossref_primary_10_1055_s_0042_1759736 crossref_primary_10_1097_TP_0000000000003999 crossref_primary_10_3390_jcm12020421 crossref_primary_10_3389_fpubh_2022_836358 crossref_primary_10_1016_j_ebiom_2022_103926 crossref_primary_10_1183_13993003_02417_2021 crossref_primary_10_1017_dmp_2022_307 crossref_primary_10_1186_s12985_021_01737_3 crossref_primary_10_1016_S2666_5247_22_00290_7 crossref_primary_10_1080_14760584_2022_2148659 crossref_primary_10_31631_2073_3046_2022_21_4_113_118 crossref_primary_10_3390_pr10112213 crossref_primary_10_3390_cells13030203 crossref_primary_10_3389_fnut_2023_1275307 crossref_primary_10_3389_fimmu_2022_833085 crossref_primary_10_7759_cureus_54760 crossref_primary_10_3390_pathogens11121484 crossref_primary_10_1007_s13300_022_01206_2 crossref_primary_10_1038_s41375_023_01920_1 crossref_primary_10_2139_ssrn_4192465 crossref_primary_10_1038_s41432_024_01014_6 crossref_primary_10_3389_fcvm_2024_1409723 crossref_primary_10_1038_s41467_022_35781_6 crossref_primary_10_1136_ebnurs_2022_103613 crossref_primary_10_3390_pathogens11121479 crossref_primary_10_3390_vaccines11091427 crossref_primary_10_1007_s11517_022_02540_0 crossref_primary_10_3389_fimmu_2022_978977 crossref_primary_10_1016_j_heliyon_2023_e15653 crossref_primary_10_1128_jvi_01571_23 crossref_primary_10_3390_healthcare12141365 crossref_primary_10_3390_vaccines11101578 crossref_primary_10_1128_spectrum_01100_23 crossref_primary_10_1177_03000605221090363 crossref_primary_10_1126_sciimmunol_ade6132 crossref_primary_10_3390_ijms231911058 crossref_primary_10_1007_s00253_023_12490_8 crossref_primary_10_1017_S0950268821002430 crossref_primary_10_1515_mr_2021_0021 crossref_primary_10_3390_vaccines10111844 crossref_primary_10_1007_s12275_022_1499_z crossref_primary_10_1073_pnas_2302245120 crossref_primary_10_3390_life13030617 crossref_primary_10_2807_1560_7917_ES_2023_28_47_2300186 crossref_primary_10_3389_fimmu_2022_985478 crossref_primary_10_3390_v13102095 crossref_primary_10_3390_pharmaceutics14071448 crossref_primary_10_3390_v15040999 crossref_primary_10_1002_jmv_29051 crossref_primary_10_1016_j_vaccine_2023_03_029 crossref_primary_10_1007_s12032_023_01997_9 crossref_primary_10_15212_AMM_2023_0033 crossref_primary_10_3389_fchem_2022_832431 crossref_primary_10_3390_ph16081131 crossref_primary_10_1002_ange_202310395 crossref_primary_10_1016_j_psycom_2022_100054 crossref_primary_10_1016_j_tmaid_2023_102563 crossref_primary_10_3390_vaccines10071155 crossref_primary_10_1126_sciadv_abp9961 crossref_primary_10_1097_MOT_0000000000001056 crossref_primary_10_1128_spectrum_04081_22 crossref_primary_10_1007_s10910_023_01512_5 crossref_primary_10_1016_j_bsheal_2022_06_001 crossref_primary_10_1038_s41565_022_01174_5 crossref_primary_10_2105_AJPH_2022_307112 crossref_primary_10_2147_PPA_S393956 crossref_primary_10_54097_hset_v45i_7483 crossref_primary_10_1016_j_vaccine_2023_03_036 crossref_primary_10_58395_hb45xe74 crossref_primary_10_1016_j_meegid_2023_105480 crossref_primary_10_1055_a_1699_5440 crossref_primary_10_1001_jamanetworkopen_2023_10302 crossref_primary_10_1371_journal_pone_0272954 crossref_primary_10_3390_biomedicines10112801 crossref_primary_10_1007_s13337_022_00755_1 crossref_primary_10_1055_s_0042_1759779 crossref_primary_10_3390_s23208365 crossref_primary_10_1093_infdis_jiac318 crossref_primary_10_1016_j_heliyon_2024_e25889 crossref_primary_10_1016_j_mser_2023_100715 crossref_primary_10_1016_j_cmi_2023_12_010 crossref_primary_10_1126_science_abq3773 crossref_primary_10_3390_vaccines11020301 crossref_primary_10_1186_s40001_022_00874_x crossref_primary_10_1016_S2468_1253_22_00274_6 crossref_primary_10_2139_ssrn_3990239 crossref_primary_10_1016_j_biopha_2022_113766 crossref_primary_10_1016_j_bspc_2022_104107 crossref_primary_10_1016_j_bmcl_2022_128629 crossref_primary_10_1128_mbio_00519_22 crossref_primary_10_38053_acmj_1218224 crossref_primary_10_3390_vaccines10030426 crossref_primary_10_1371_journal_pmed_1004018 crossref_primary_10_1371_journal_pone_0261930 crossref_primary_10_3390_jpm11121243 crossref_primary_10_1016_j_ejmech_2023_115667 crossref_primary_10_1080_22221751_2022_2130101 crossref_primary_10_3389_fimmu_2022_834098 crossref_primary_10_3390_vaccines11050905 crossref_primary_10_3346_jkms_2022_37_e267 crossref_primary_10_1016_j_ebiom_2021_103677 crossref_primary_10_24018_ejmed_2021_3_6_1120 crossref_primary_10_1038_s41467_023_38275_1 crossref_primary_10_1002_advs_202104495 crossref_primary_10_1016_j_vaccine_2023_05_056 crossref_primary_10_1080_14760584_2023_2191716 crossref_primary_10_53879_id_61_02_14233 crossref_primary_10_1016_j_jcvp_2022_100121 crossref_primary_10_1016_j_msard_2022_103708 crossref_primary_10_3390_app12115546 crossref_primary_10_1097_SPC_0000000000000601 crossref_primary_10_3389_fimmu_2022_849465 crossref_primary_10_3390_vaccines10071093 crossref_primary_10_1016_j_coi_2022_102234 crossref_primary_10_3389_fmed_2021_809395 crossref_primary_10_1177_2632010X231218075 crossref_primary_10_1016_j_bcp_2024_116218 crossref_primary_10_1080_22221751_2022_2027219 crossref_primary_10_1038_s41598_022_07952_4 crossref_primary_10_3390_vaccines11091441 crossref_primary_10_1038_s41541_022_00507_8 crossref_primary_10_1161_CIRCRESAHA_122_319954 crossref_primary_10_1136_bmjopen_2022_062187 crossref_primary_10_3389_fimmu_2022_1042784 crossref_primary_10_1080_21645515_2022_2110409 crossref_primary_10_1007_s11427_022_2273_3 crossref_primary_10_3390_vaccines10030448 crossref_primary_10_1016_j_puhe_2023_02_020 crossref_primary_10_3390_biomed2020015 crossref_primary_10_1080_14760584_2022_2112571 crossref_primary_10_2169_internalmedicine_2335_23 crossref_primary_10_3390_ijms242216392 crossref_primary_10_4081_mrm_2023_906 crossref_primary_10_1002_jmv_29098 crossref_primary_10_1007_s13278_023_01155_z crossref_primary_10_1016_j_hlife_2024_05_004 crossref_primary_10_3390_vaccines10040591 crossref_primary_10_1038_s41392_022_01002_1 crossref_primary_10_3390_toxins15090563 crossref_primary_10_3389_fchem_2022_864206 crossref_primary_10_2147_OPTH_S342300 crossref_primary_10_3390_vaccines11091458 crossref_primary_10_1016_j_virs_2022_12_008 crossref_primary_10_1038_s41598_022_21884_z crossref_primary_10_1002_cam4_7304 crossref_primary_10_2807_1560_7917_ES_2022_27_10_2200222 crossref_primary_10_3389_fpubh_2022_842862 crossref_primary_10_3390_rs13234946 crossref_primary_10_4014_jmb_2111_11026 crossref_primary_10_1080_07853890_2023_2195204 crossref_primary_10_1038_s41467_023_39189_8 crossref_primary_10_1016_S2214_109X_22_00233_9 crossref_primary_10_4081_monaldi_2023_2771 crossref_primary_10_1080_21645515_2024_2322795 crossref_primary_10_1007_s40258_024_00880_6 crossref_primary_10_1155_2023_7061783 crossref_primary_10_1016_j_biopha_2024_116441 crossref_primary_10_1093_cid_ciac057 crossref_primary_10_1098_rsos_211021 crossref_primary_10_1039_D1BM01060C crossref_primary_10_1093_infdis_jiad329 crossref_primary_10_1097_CM9_0000000000002767 crossref_primary_10_1016_j_biopha_2022_112756 crossref_primary_10_1016_j_puhe_2023_11_003 crossref_primary_10_21070_acopen_8_2023_7843 crossref_primary_10_1016_j_esmoop_2023_101607 crossref_primary_10_1146_annurev_economics_051520_025412 crossref_primary_10_3390_idr14060099 crossref_primary_10_1007_s10072_021_05798_8 crossref_primary_10_1007_s11135_023_01698_5 crossref_primary_10_3389_frym_2023_1100502 crossref_primary_10_1016_j_amc_2024_128617 crossref_primary_10_20518_tjph_1028261 crossref_primary_10_3389_fimmu_2023_1126392 crossref_primary_10_5195_pom_2023_138 crossref_primary_10_3390_v14050961 crossref_primary_10_1016_j_metabol_2021_155121 crossref_primary_10_2139_ssrn_3980910 crossref_primary_10_6000_1929_6029_2022_11_22 crossref_primary_10_61182_rnavmed_v8n1a5 crossref_primary_10_1007_s10238_023_01046_9 crossref_primary_10_1055_s_0041_1736169 crossref_primary_10_3389_fimmu_2022_1041185 crossref_primary_10_1126_science_abn1755 crossref_primary_10_1080_21645515_2022_2065824 crossref_primary_10_1038_s42003_022_03849_0 crossref_primary_10_1080_08927022_2022_2111421 crossref_primary_10_3390_vaccines10111899 crossref_primary_10_7759_cureus_40878 crossref_primary_10_1057_s41599_022_01106_7 crossref_primary_10_1128_spectrum_02857_23 crossref_primary_10_1172_jci_insight_155655 crossref_primary_10_1016_j_eclinm_2023_102231 crossref_primary_10_1021_acs_joc_2c01897 crossref_primary_10_3390_genes13111941 crossref_primary_10_3390_tropicalmed7070118 crossref_primary_10_1016_j_idcr_2022_e01582 crossref_primary_10_2147_IDR_S441538 crossref_primary_10_1096_fj_202101492R crossref_primary_10_3390_vaccines11050957 crossref_primary_10_3389_fimmu_2023_1131985 crossref_primary_10_3390_ijerph19094930 crossref_primary_10_3389_fimmu_2022_947602 crossref_primary_10_1038_s41541_024_00840_0 crossref_primary_10_1371_journal_pone_0289255 crossref_primary_10_3389_fimmu_2024_1365803 crossref_primary_10_1016_j_isci_2023_107224 crossref_primary_10_1111_cbdd_14383 crossref_primary_10_3389_fpubh_2024_1339267 crossref_primary_10_1016_j_ebiom_2022_103986 crossref_primary_10_1016_j_jiac_2022_03_014 crossref_primary_10_1093_infdis_jiad306 crossref_primary_10_1515_cclm_2023_0129 crossref_primary_10_1128_spectrum_02892_23 crossref_primary_10_3389_fpsyg_2022_982634 crossref_primary_10_3390_vaccines10010072 crossref_primary_10_1002_jmv_28245 crossref_primary_10_3390_vaccines10081353 crossref_primary_10_1177_20420986231165674 crossref_primary_10_1038_s41564_022_01166_0 crossref_primary_10_1038_s42003_023_04689_2 crossref_primary_10_3389_fimmu_2021_766821 crossref_primary_10_3390_ijms23147702 crossref_primary_10_2217_nnm_2023_0122 crossref_primary_10_1002_cbic_202300301 crossref_primary_10_3390_brainsci12020190 crossref_primary_10_1016_j_physa_2022_128041 crossref_primary_10_3390_vaccines11050987 crossref_primary_10_2147_PPA_S431148 crossref_primary_10_1142_S021833902450013X crossref_primary_10_5798_dicletip_1411963 crossref_primary_10_3390_ijerph191610154 crossref_primary_10_3390_vaccines11050969 crossref_primary_10_1360_nso_20220007 crossref_primary_10_1038_s41392_022_00996_y crossref_primary_10_3390_vaccines11101625 crossref_primary_10_3390_molecules27175620 crossref_primary_10_3390_biomedicines10020338 crossref_primary_10_3390_v14040803 crossref_primary_10_1038_s41392_023_01656_5 crossref_primary_10_1093_eurheartjsupp_suac123 crossref_primary_10_1016_j_vaccine_2023_09_013 crossref_primary_10_1057_s41599_023_02406_2 crossref_primary_10_1080_21645515_2023_2275962 crossref_primary_10_1002_jmv_28377 crossref_primary_10_3390_ijerph192113902 crossref_primary_10_2139_ssrn_4112153 crossref_primary_10_1038_s41598_023_38743_0 crossref_primary_10_1038_s43856_022_00173_w crossref_primary_10_15789_2220_7619_IAF_1998 crossref_primary_10_1128_mbio_02320_23 crossref_primary_10_3389_fpubh_2022_1031241 crossref_primary_10_1002_jmv_28011 crossref_primary_10_1016_j_pmedr_2022_101812 crossref_primary_10_3390_vaccines10081224 crossref_primary_10_1038_s41467_024_47450_x crossref_primary_10_3390_vaccines12040402 crossref_primary_10_1016_j_tranpol_2024_01_009 crossref_primary_10_3390_vaccines11071217 crossref_primary_10_1038_s41575_022_00698_4 crossref_primary_10_3390_microorganisms11030580 crossref_primary_10_1016_j_drup_2024_101098 crossref_primary_10_2196_35754 crossref_primary_10_1093_ofid_ofac544 crossref_primary_10_3346_jkms_2023_38_e106 crossref_primary_10_3390_vaccines10071123 crossref_primary_10_1038_s41591_022_01721_6 crossref_primary_10_1002_jmv_29115 crossref_primary_10_1038_s41418_024_01278_6 crossref_primary_10_1073_pnas_2205784119 crossref_primary_10_1016_j_amjoto_2023_103970 crossref_primary_10_1155_2022_5721212 crossref_primary_10_3390_antiox11020354 crossref_primary_10_1016_j_jinf_2022_02_009 crossref_primary_10_1016_j_nantod_2022_101580 crossref_primary_10_3389_fmicb_2022_889643 crossref_primary_10_1111_imr_13112 crossref_primary_10_3390_ijerph21070892 crossref_primary_10_3390_vaccines9101165 crossref_primary_10_1016_j_urology_2022_05_037 crossref_primary_10_1021_acs_jmedchem_2c00303 crossref_primary_10_1016_j_vaccine_2024_04_079 crossref_primary_10_33393_dti_2024_3059 crossref_primary_10_1016_j_autrev_2024_103543 crossref_primary_10_1038_s41588_022_01042_x crossref_primary_10_1080_14760584_2024_2334423 crossref_primary_10_3390_vaccines10111851 crossref_primary_10_1016_j_vaccine_2022_09_059 crossref_primary_10_1080_21645515_2021_2024066 crossref_primary_10_1007_s13238_021_00883_2 crossref_primary_10_3390_idr14040057 crossref_primary_10_3389_fimmu_2022_1041025 crossref_primary_10_3390_v14020387 crossref_primary_10_1016_j_cities_2022_103865 crossref_primary_10_1051_epjconf_202226301002 crossref_primary_10_3390_vaccines11040723 crossref_primary_10_3390_vaccines10081167 crossref_primary_10_1002_jmv_29488 crossref_primary_10_3389_fpubh_2022_995382 crossref_primary_10_1038_s41379_022_01069_9 crossref_primary_10_1111_exd_14825 crossref_primary_10_1038_s41598_022_11060_8 crossref_primary_10_1186_s12865_024_00617_z crossref_primary_10_1016_j_coph_2021_11_002 crossref_primary_10_1126_scitranslmed_abq1945 crossref_primary_10_1016_j_vaccine_2023_01_024 crossref_primary_10_1016_j_scib_2022_05_018 crossref_primary_10_1002_jmv_28275 crossref_primary_10_2169_internalmedicine_8568_21 crossref_primary_10_1371_journal_ppat_1010802 crossref_primary_10_1186_s43042_022_00314_9 crossref_primary_10_1093_procel_pwae007 crossref_primary_10_1093_cid_ciad562 crossref_primary_10_1093_cid_ciac470 crossref_primary_10_3389_fmed_2023_1236702 crossref_primary_10_1038_s41467_022_30222_w crossref_primary_10_1109_TUFFC_2022_3211532 crossref_primary_10_3390_pharmaceutics14122554 crossref_primary_10_1111_bph_16063 crossref_primary_10_5005_jp_journals_10018_1405 crossref_primary_10_1186_s12865_022_00532_1 crossref_primary_10_1007_s13555_021_00610_z crossref_primary_10_1016_j_jiph_2022_11_028 crossref_primary_10_2139_ssrn_4001786 crossref_primary_10_1016_j_amjsurg_2022_08_021 crossref_primary_10_1016_j_ijregi_2023_09_007 crossref_primary_10_1111_ans_17654 crossref_primary_10_3390_v15091786 crossref_primary_10_1002_jmv_28163 crossref_primary_10_1016_j_jiac_2022_02_016 crossref_primary_10_1016_j_ejps_2023_106489 crossref_primary_10_1080_13548506_2022_2159049 crossref_primary_10_1186_s12916_024_03295_1 crossref_primary_10_1371_journal_pone_0290412 crossref_primary_10_1016_j_celrep_2022_111160 crossref_primary_10_1371_journal_pone_0276008 crossref_primary_10_3389_fimmu_2022_816389 crossref_primary_10_21467_ajgr_11_1_52_60 crossref_primary_10_1177_17475198231184799 crossref_primary_10_1080_21645515_2022_2082171 crossref_primary_10_1021_acsami_4c01384 crossref_primary_10_1371_journal_pone_0280627 crossref_primary_10_1177_19417381231208677 crossref_primary_10_3390_vaccines11030706 crossref_primary_10_1017_S0950268823001085 crossref_primary_10_3389_fimmu_2023_1131965 crossref_primary_10_3892_mmr_2022_12779 crossref_primary_10_1016_j_vaccine_2024_04_052 crossref_primary_10_1021_acs_jafc_2c09180 crossref_primary_10_1016_j_heliyon_2023_e23944 crossref_primary_10_1016_j_amepre_2021_11_006 crossref_primary_10_3389_fimmu_2022_836923 crossref_primary_10_1073_pnas_2220403120 crossref_primary_10_3390_v14040759 crossref_primary_10_3390_vaccines9111297 crossref_primary_10_1016_j_bbrc_2024_150231 crossref_primary_10_3390_vaccines11040875 crossref_primary_10_4274_jcp_2022_38802 crossref_primary_10_1016_j_antiviral_2022_105473 crossref_primary_10_3389_fimmu_2022_981693 crossref_primary_10_1002_mco2_228 crossref_primary_10_1016_j_jhepr_2022_100605 crossref_primary_10_1017_S0950268822000255 crossref_primary_10_3390_biology11101531 crossref_primary_10_1016_j_jaci_2023_12_011 crossref_primary_10_3390_metabo11100699 crossref_primary_10_1155_2023_4588659 crossref_primary_10_3389_fimmu_2023_1135815 crossref_primary_10_1016_j_ymthe_2021_09_024 crossref_primary_10_1080_21645515_2023_2246542 crossref_primary_10_1172_jci_insight_160039 crossref_primary_10_1021_jacs_3c04115 crossref_primary_10_2196_44839 crossref_primary_10_1016_j_ijbiomac_2022_09_204 crossref_primary_10_3389_fimmu_2022_893943 crossref_primary_10_1007_s00284_021_02724_1 crossref_primary_10_3389_fimmu_2023_1119564 crossref_primary_10_1093_oncolo_oyac196 crossref_primary_10_47836_mjmhs_19_4_35 crossref_primary_10_3390_ijms23116123 crossref_primary_10_3389_fpubh_2022_878208 crossref_primary_10_1021_acsinfecdis_3c00418 crossref_primary_10_3389_fmed_2021_784002 crossref_primary_10_1002_jmv_28630 crossref_primary_10_1002_jmv_28751 crossref_primary_10_3390_vaccines10010107 crossref_primary_10_1038_s41591_024_02955_2 crossref_primary_10_4049_jimmunol_2300783 crossref_primary_10_1038_s41562_023_01591_z crossref_primary_10_31260_RepertMedCir_01217372_1329 crossref_primary_10_1080_10408363_2024_2350374 crossref_primary_10_3389_fphar_2023_1185076 crossref_primary_10_1016_j_bmcl_2023_129214 crossref_primary_10_1093_pubmed_fdad277 crossref_primary_10_3390_ijerph19084842 crossref_primary_10_1186_s13020_023_00877_8 crossref_primary_10_3390_su14095566 crossref_primary_10_1002_jmv_29611 crossref_primary_10_1038_s41598_022_24464_3 crossref_primary_10_3390_vaccines11030615 crossref_primary_10_1007_s44229_022_00006_x crossref_primary_10_1016_S1473_3099_22_00433_9 crossref_primary_10_1016_j_vaccine_2024_02_028 crossref_primary_10_1111_resp_14305 crossref_primary_10_13181_mji_bc_226066 crossref_primary_10_3390_ijerph20105877 crossref_primary_10_3389_fonc_2023_1147590 crossref_primary_10_1016_j_mbs_2023_109109 crossref_primary_10_3389_fimmu_2022_828053 crossref_primary_10_1016_j_jtauto_2023_100214 crossref_primary_10_3389_fimmu_2024_1363572 crossref_primary_10_1016_j_clinbiochem_2023_110607 crossref_primary_10_21833_ijaas_2023_01_020 crossref_primary_10_1016_j_tim_2023_07_006 crossref_primary_10_1021_acs_biomac_2c00271 crossref_primary_10_3389_fimmu_2023_1296603 crossref_primary_10_3389_fimmu_2024_1382911 crossref_primary_10_1039_D2CC00271J crossref_primary_10_1038_s41467_022_31395_0 crossref_primary_10_3390_diseases10040112 crossref_primary_10_1016_j_vaccine_2023_08_054 crossref_primary_10_7759_cureus_50619 crossref_primary_10_1016_j_fitote_2023_105784 crossref_primary_10_3390_vaccines10091494 crossref_primary_10_1016_j_idm_2023_11_003 crossref_primary_10_55453_rjmm_2022_125_3_8 crossref_primary_10_35621_23587490_v10_n1_p892_903 crossref_primary_10_1016_j_cell_2021_12_033 crossref_primary_10_3390_molecules27041178 crossref_primary_10_3389_fmed_2022_849217 crossref_primary_10_1016_j_vaccine_2022_07_051 crossref_primary_10_1080_21645515_2022_2158012 crossref_primary_10_3390_ijerph182212024 crossref_primary_10_3390_vaccines9111259 crossref_primary_10_1016_j_jiph_2022_03_014 crossref_primary_10_1126_sciimmunol_add4853 crossref_primary_10_1111_bjhp_12632 crossref_primary_10_1186_s12879_024_09435_5 crossref_primary_10_3389_fimmu_2023_1098461 crossref_primary_10_1016_j_jdmm_2021_100664 crossref_primary_10_3389_fnano_2022_987034 crossref_primary_10_1093_infdis_jiad089 crossref_primary_10_1038_s41598_022_05036_x crossref_primary_10_1186_s12967_023_04553_1 crossref_primary_10_3201_eid2811_221127 crossref_primary_10_3389_fmed_2022_1054557 crossref_primary_10_1093_cvr_cvac139 crossref_primary_10_3390_v16010082 crossref_primary_10_3390_vaccines10081215 crossref_primary_10_1002_mco2_143 crossref_primary_10_37349_eaa_2024_00028 crossref_primary_10_3389_fimmu_2022_995412 crossref_primary_10_3390_ph15010021 crossref_primary_10_3390_vaccines11010170 crossref_primary_10_3390_medicina58020144 crossref_primary_10_1016_j_intimp_2023_109728 crossref_primary_10_3389_fmed_2022_965790 crossref_primary_10_3390_v15020530 crossref_primary_10_1016_j_jeca_2023_e00331 crossref_primary_10_22416_1382_4376_2022_32_3_23_28 crossref_primary_10_1093_ofid_ofac138 crossref_primary_10_1080_07853890_2023_2274510 crossref_primary_10_3390_ijms23020835 crossref_primary_10_1016_j_heliyon_2023_e13952 crossref_primary_10_3390_biomedicines10081787 crossref_primary_10_3390_ph15101298 crossref_primary_10_1017_S1473550422000258 crossref_primary_10_1016_j_vaccine_2021_10_007 crossref_primary_10_3390_v14122620 crossref_primary_10_3390_v15030692 crossref_primary_10_1093_rheumatology_keac574 crossref_primary_10_1002_eji_202249841 crossref_primary_10_1017_dmp_2022_282 crossref_primary_10_1515_cclm_2022_0914 crossref_primary_10_3390_su14084624 crossref_primary_10_1021_acsnanoscienceau_2c00062 crossref_primary_10_2147_IDR_S421938 crossref_primary_10_3389_fcell_2021_792335 crossref_primary_10_1371_journal_pone_0277505 crossref_primary_10_3390_ijms24043387 crossref_primary_10_1016_j_micpath_2022_105828 crossref_primary_10_1002_adhm_202303261 crossref_primary_10_1016_j_antiviral_2023_105653 crossref_primary_10_3389_ti_2023_11286 crossref_primary_10_1177_03946320221128534 crossref_primary_10_3390_vaccines11030533 crossref_primary_10_1016_j_patol_2022_09_003 crossref_primary_10_3389_fpubh_2022_1054313 crossref_primary_10_3389_fpubh_2022_815036 crossref_primary_10_3389_fimmu_2023_1030810 crossref_primary_10_1002_jmv_29416 crossref_primary_10_3390_v16010065 crossref_primary_10_1007_s10792_024_03119_4 crossref_primary_10_1016_j_antiviral_2022_105450 crossref_primary_10_1016_S2666_5247_23_00324_5 crossref_primary_10_3390_vaccines10060977 crossref_primary_10_1002_mco2_126 crossref_primary_10_3390_vaccines10101689 crossref_primary_10_1016_j_phrs_2022_106412 crossref_primary_10_1038_s41598_022_24519_5 crossref_primary_10_1371_journal_pone_0266844 crossref_primary_10_1093_infdis_jiac092 crossref_primary_10_3390_v14091939 crossref_primary_10_1093_pnasnexus_pgad192 crossref_primary_10_1016_j_bioelechem_2023_108632 crossref_primary_10_3389_fmed_2022_828402 crossref_primary_10_3390_vaccines11010152 crossref_primary_10_35366_105422 crossref_primary_10_3389_fimmu_2023_1129245 crossref_primary_10_1038_s41408_021_00594_1 crossref_primary_10_1099_jgv_0_001765 crossref_primary_10_1080_22221751_2022_2056524 crossref_primary_10_1080_21645515_2022_2062971 crossref_primary_10_3390_cancers14225547 crossref_primary_10_3390_ijerph19084876 crossref_primary_10_1016_j_tips_2022_06_001 crossref_primary_10_1016_j_cell_2021_09_010 crossref_primary_10_1007_s13187_024_02410_3 crossref_primary_10_1038_s41467_024_49443_2 crossref_primary_10_1111_imm_13429 crossref_primary_10_3892_etm_2024_12482 crossref_primary_10_1186_s12879_022_07380_9 crossref_primary_10_1136_bmj_n2320 crossref_primary_10_23736_S2724_6329_23_04805_2 crossref_primary_10_3389_fimmu_2022_845887 crossref_primary_10_1128_jvi_01337_22 crossref_primary_10_1016_j_jbc_2023_104746 crossref_primary_10_1208_s12248_022_00754_6 crossref_primary_10_1021_acsinfecdis_1c00629 crossref_primary_10_3390_ph15040445 crossref_primary_10_1002_jmv_27808 crossref_primary_10_1016_j_jiac_2022_07_010 crossref_primary_10_1038_s41598_022_19414_y crossref_primary_10_1186_s40246_022_00392_1 crossref_primary_10_1016_j_trim_2023_101864 crossref_primary_10_1038_s41598_023_42194_y crossref_primary_10_3390_genes15030361 crossref_primary_10_3390_pathogens11121531 crossref_primary_10_1007_s00430_023_00776_7 crossref_primary_10_3389_bjbs_2022_10426 crossref_primary_10_1093_pnasnexus_pgac159 crossref_primary_10_3389_fpubh_2022_877621 crossref_primary_10_1021_acs_jcim_3c00409 crossref_primary_10_1080_21645515_2024_2355683 crossref_primary_10_1186_s12982_024_00140_x crossref_primary_10_1007_s10792_023_02795_y crossref_primary_10_3390_covid3100106 crossref_primary_10_1016_j_jiph_2023_10_007 crossref_primary_10_1016_j_ebiom_2023_104574 crossref_primary_10_3390_ijms24109094 crossref_primary_10_1016_j_ebiom_2022_104297 crossref_primary_10_1016_j_xcrm_2022_100520 crossref_primary_10_1080_13669877_2021_2001674 crossref_primary_10_1007_s43538_023_00176_8 crossref_primary_10_12677_acm_2024_1451694 crossref_primary_10_1016_j_vaccine_2024_01_080 crossref_primary_10_1093_cid_ciac961 crossref_primary_10_1016_j_cytogfr_2023_11_005 crossref_primary_10_2478_acph_2023_0020 crossref_primary_10_1038_s41422_022_00612_2 crossref_primary_10_3389_fimmu_2023_1172851 crossref_primary_10_3390_ijms25052532 crossref_primary_10_1016_j_bbrc_2021_12_079 crossref_primary_10_1186_s13287_023_03556_5 crossref_primary_10_3389_fimmu_2022_911859 crossref_primary_10_3389_fimmu_2021_766278 crossref_primary_10_1016_j_procbio_2022_12_002 crossref_primary_10_3390_diagnostics12061315 crossref_primary_10_1002_pro_4991 crossref_primary_10_1038_s41598_023_37072_6 crossref_primary_10_1016_j_heliyon_2023_e13285 crossref_primary_10_1111_all_15593 crossref_primary_10_1038_s41541_023_00691_1 crossref_primary_10_1016_j_apm_2022_09_017 crossref_primary_10_1136_ard_2022_222550 crossref_primary_10_1126_sciimmunol_abo2202 crossref_primary_10_1007_s00284_023_03322_z crossref_primary_10_1016_j_medj_2022_04_013 crossref_primary_10_1016_j_antiviral_2023_105576 crossref_primary_10_3390_molecules27030658 crossref_primary_10_1093_oxfimm_iqac004 crossref_primary_10_1093_infdis_jiae074 crossref_primary_10_1186_s12879_022_07878_2 crossref_primary_10_2139_ssrn_4141240 crossref_primary_10_3389_fimmu_2024_1357731 crossref_primary_10_3389_fmed_2024_1322440 crossref_primary_10_1186_s12967_023_04787_z crossref_primary_10_1007_s00018_022_04246_w crossref_primary_10_1002_nau_25261 crossref_primary_10_1016_j_comcom_2022_10_013 crossref_primary_10_3390_vaccines10020323 crossref_primary_10_1021_acsomega_3c07845 crossref_primary_10_1038_s41590_021_01122_w crossref_primary_10_3389_fcimb_2021_777212 crossref_primary_10_1016_j_bbadis_2022_166432 crossref_primary_10_1126_sciimmunol_adf0348 crossref_primary_10_2174_1871525721666230406075646 crossref_primary_10_1038_s41467_024_49744_6 crossref_primary_10_3390_vaccines11010118 crossref_primary_10_1186_s12889_023_15118_8 crossref_primary_10_1111_imr_13088 crossref_primary_10_1002_iid3_1000 crossref_primary_10_1016_j_chaos_2021_111789 crossref_primary_10_1016_j_bbrc_2022_07_087 crossref_primary_10_1016_j_omtn_2023_102045 crossref_primary_10_1038_s41573_023_00672_y crossref_primary_10_1080_22221751_2023_2249130 crossref_primary_10_1038_s41467_023_37336_9 crossref_primary_10_1002_adfm_202206055 crossref_primary_10_1038_s41467_022_34297_3 crossref_primary_10_1002_anie_202310395 crossref_primary_10_1126_scitranslmed_abn9237 crossref_primary_10_3389_fimmu_2022_994173 crossref_primary_10_3389_fimmu_2022_850987 crossref_primary_10_3390_jpm12050849 crossref_primary_10_1016_j_anai_2021_11_014 crossref_primary_10_7759_cureus_23526 crossref_primary_10_1007_s00011_022_01567_1 crossref_primary_10_2139_ssrn_3985605 crossref_primary_10_1093_oxfimm_iqae001 crossref_primary_10_1097_QAD_0000000000003758 crossref_primary_10_1111_1756_185X_15166 crossref_primary_10_1038_s41422_022_00746_3 crossref_primary_10_7759_cureus_58904 crossref_primary_10_1186_s12951_023_01981_5 crossref_primary_10_1002_pan3_10396 crossref_primary_10_1007_s12553_022_00676_5 crossref_primary_10_1038_s41598_023_48397_7 crossref_primary_10_3390_ijms232214193 crossref_primary_10_1038_s41392_022_00910_6 crossref_primary_10_1136_bmjph_2023_000282 crossref_primary_10_3390_ijerph19063219 crossref_primary_10_1002_jmv_28946 crossref_primary_10_1080_22221751_2022_2122580 crossref_primary_10_1038_s41392_023_01420_9 crossref_primary_10_1016_j_jiac_2022_12_016 crossref_primary_10_3390_ijerph19052538 crossref_primary_10_3390_jcm10245876 crossref_primary_10_1089_dna_2021_0457 crossref_primary_10_3390_vaccines9121442 crossref_primary_10_1007_s44197_023_00092_6 crossref_primary_10_1016_j_jad_2023_09_025 crossref_primary_10_1016_S2214_109X_21_00501_5 crossref_primary_10_1080_15548627_2023_2291939 crossref_primary_10_1186_s12913_024_11094_w crossref_primary_10_1007_s12274_021_3832_y crossref_primary_10_1038_s42949_024_00166_9 crossref_primary_10_1016_j_talanta_2024_126403 crossref_primary_10_1177_08901171221075019 crossref_primary_10_1016_j_rinp_2022_106011 crossref_primary_10_1016_j_ijhm_2024_103722 crossref_primary_10_3390_cimb46030124 crossref_primary_10_1093_pnasnexus_pgad223 crossref_primary_10_1038_s41392_023_01640_z crossref_primary_10_1016_j_antiviral_2024_105898 crossref_primary_10_1186_s13643_022_01958_9 crossref_primary_10_3390_vaccines9111317 crossref_primary_10_1016_j_jvacx_2023_100404 crossref_primary_10_1016_j_engmic_2024_100162 crossref_primary_10_1016_j_chom_2023_11_012 crossref_primary_10_1016_j_omtn_2022_11_024 crossref_primary_10_1038_s41598_022_23235_4 crossref_primary_10_1371_journal_pone_0273430 crossref_primary_10_1136_bmj_n2034 crossref_primary_10_3389_fbioe_2023_1135997 crossref_primary_10_14336_AD_2022_0718 crossref_primary_10_1016_j_omtm_2024_101189 crossref_primary_10_1016_j_ebiom_2022_104196 crossref_primary_10_1016_j_vaccine_2022_10_014 crossref_primary_10_1016_j_idm_2023_07_002 crossref_primary_10_1016_j_vaccine_2022_04_020 crossref_primary_10_1080_21645515_2021_1995283 crossref_primary_10_1007_s15010_021_01751_1 crossref_primary_10_1016_j_chaos_2023_114139 crossref_primary_10_1038_s41418_021_00909_6 crossref_primary_10_1016_j_epidem_2022_100618 crossref_primary_10_1016_j_lanwpc_2022_100389 crossref_primary_10_4062_biomolther_2023_006 crossref_primary_10_3390_cells11162496 crossref_primary_10_1038_s41590_022_01351_7 crossref_primary_10_1371_journal_pone_0281281 crossref_primary_10_1093_discim_kyad030 crossref_primary_10_1186_s12951_022_01558_8 crossref_primary_10_3390_v14040685 crossref_primary_10_1002_hsr2_1041 crossref_primary_10_1039_D4RA02593H crossref_primary_10_5937_mp74_47686 crossref_primary_10_1038_s41392_022_00920_4 crossref_primary_10_3389_fnut_2023_1152254 crossref_primary_10_1136_bmjopen_2022_060838
Cites_doi	10.1038/s41562-021-01122-8 10.1056/NEJMoa2105385 10.1101/2021.05.15.21257017 10.1016/S0140-6736(21)00628-0 10.1136/bmj.n710 10.1136/bmj.n296 10.1161/CIRCULATIONAHA.121.055913 10.1038/s41577-021-00531-0 10.1056/NEJMc2104974 10.21203/RS.3.RS-612205/V1 10.21203/rs.3.rs-440461/v1 10.1038/s41591-021-01270-4 10.1038/s41591-021-01285-x 10.1017/ice.2021.199 10.1038/d41586-021-01661-0 10.1046/j.1525-139X.2003.03013.x 10.1126/science.abh2644 10.1001/jama.2021.1967 10.1038/s41591-021-01230-y 10.1101/2021.06.21.21258528 10.1056/nejmoa2102214 10.1093/cid/ciab361 10.1126/science.abg6105 10.1016/S0140-6736(21)01358-1 10.1056/NEJMoa2101544 10.1371/journal.pbio.3001211 10.1038/s41577-021-00556-5 10.1038/s41586-021-03324-6 10.1101/2021.05.04.21256613 10.1136/bmj.n1114 10.1038/s41586-021-03647-4 10.1016/S0140-6736(21)00677-2 10.1016/S0140-6736(20)32661-1 10.1016/S0140-6736(21)01290-3 10.1136/bmj.n1088 10.1056/NEJMoa2104840 10.1056/NEJMoa2034577 10.1016/S2468-2667(21)00055-4 10.1038/d41586-021-00268-9 10.1128/CVI.05053-11 10.1093/infdis/jis342 10.1161/STROKEAHA.116.013617 10.21203/rs.3.rs-404769/v1 10.1371/journal.pone.0243597 10.1101/2021.04.12.21255308 10.1038/d41586-021-00094-z 10.1101/2021.04.13.439482 10.1016/S0140-6736(21)00790-X 10.1056/NEJMoa2107715 10.1056/NEJMc2102179 10.1038/s41586-021-03398-2 10.1101/2021.03.30.21254655 10.1038/s41586-021-03693-y 10.1056/NEJMoa2035389 10.1016/j.vaccine.2021.05.063 10.1038/s41467-020-18450-4 10.1016/S0140-6736(21)01115-6 10.1038/s41591-021-01377-8. 10.1038/s41541-021-00336-1 10.1056/nejmc2102017 10.1016/S0140-6736(21)00432-3 10.1101/2021.04.22.21255911 10.1136/bmj.n338 10.1038/s41586-021-03696-9 10.1016/S0140-6736(21)00234-8 10.1002/ajh.26132 10.1080/10810730.2020.1868630 10.1101/2021.01.25.427948 10.1038/d41586-021-00119-7. 10.2807/1560-7917.ES.2021.26.24.2100509 10.1182/blood-2006-06-032524 10.21203/rs.3.rs-155394/v1 10.1038/s41392-020-00451-w 10.1038/s41591-021-01242-8
ContentType	Journal Article
Copyright	Springer Nature Limited 2021 2021. Springer Nature Limited. COPYRIGHT 2021 Nature Publishing Group Springer Nature Limited 2021.
Copyright_xml	– notice: Springer Nature Limited 2021 – notice: 2021. Springer Nature Limited. – notice: COPYRIGHT 2021 Nature Publishing Group – notice: Springer Nature Limited 2021.
DBID	CGR CUY CVF ECM EIF NPM AAYXX CITATION ISR 3V. 7QR 7RV 7T5 7U9 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB0 LK8 M0S M1P M7N M7P NAPCQ P64 PQEST PQQKQ PQUKI 5PM
DOI	10.1038/s41577-021-00592-1
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Science in Context ProQuest Central (Corporate) Chemoreception Abstracts Nursing & Allied Health Database Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Databases Natural Science Collection ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition PubMed Central (Full Participant titles)
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Central Student Technology Research Database ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Collection AIDS and Cancer Research Abstracts Chemoreception Abstracts ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest Central (Alumni)
DatabaseTitleList	MEDLINE ProQuest Central Student
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Biology
EISSN	1474-1741
EndPage	636
ExternalDocumentID	A676881824 10_1038_s41577_021_00592_1 34373623
Genre	Journal Article Review
GeographicLocations	United Kingdom
GeographicLocations_xml	– name: United Kingdom
GroupedDBID	--- .55 0R~ 123 29M 36B 39C 3V. 4.4 53G 70F 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8R4 8R5 AAEEF AARCD AAWYQ AAZLF ABAWZ ABDBF ABJNI ABLJU ABUWG ABVXF ACGFS ACIWK ACPRK ADBBV AENEX AFBBN AFKRA AFRAH AFSHS AGAYW AGEZK AGHTU AHBCP AHMBA AHOSX AHSBF AIBTJ AIYXT ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS ARMCB ASPBG AVWKF AXYYD AZFZN B0M BBNVY BENPR BHPHI BKEYQ BKKNO BPHCQ BVXVI CCPQU CS3 DB5 DU5 EAD EAP EBC EBD EBS EE. EJD EMB EMK EMOBN EPL ESX EX3 EXGXG F5P FEDTE FQGFK FSGXE FYUFA HCIFZ HMCUK HVGLF HZ~ IAO IHR IHW INH INR ISR ITC L-9 LK8 M1P M7P N9A NAPCQ NNMJJ O9- ODYON P2P PQQKQ PROAC PSQYO Q2X RNR RNT RNTTT SHXYY SIXXV SNYQT SV3 TAOOD TBHMF TDRGL TSG TUS UKHRP WOW X7M ~8M AAYZH CGR CUY CVF ECM EIF NPM AAYXX CITATION AAEXX ABEEJ ADZGE AADEA 7QR 7T5 7U9 7XB 8FD 8FK AZQEC DWQXO FR3 GNUQQ H94 K9. M7N P64 PQEST PQUKI 5PM
ID	FETCH-LOGICAL-c672t-6ba4c87e22d156eb6aadfd085e81d1250bd6dbfab9dfbd65b826e44c24e865b83
IEDL.DBID	8C1
ISSN	1474-1733
IngestDate	Tue Sep 17 21:28:57 EDT 2024 Tue Nov 19 07:09:43 EST 2024 Tue Nov 19 20:55:54 EST 2024 Tue Nov 12 22:30:04 EST 2024 Thu Aug 01 19:56:33 EDT 2024 Tue Aug 20 22:11:01 EDT 2024 Thu Nov 21 23:38:35 EST 2024 Wed Oct 16 00:40:40 EDT 2024 Fri Oct 11 20:45:52 EDT 2024
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	10
Language	English
License	2021. Springer Nature Limited. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c672t-6ba4c87e22d156eb6aadfd085e81d1250bd6dbfab9dfbd65b826e44c24e865b83
ORCID	0000-0001-8093-8741 0000-0002-1110-808X 0000-0002-0834-5201
OpenAccessLink	https://pubmed.ncbi.nlm.nih.gov/PMC8351583
PMID	34373623
PQID	2576737735
PQPubID	27582
PageCount	11
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_8351583 proquest_journals_2576737735 gale_infotracmisc_A676881824 gale_infotracacademiconefile_A676881824 gale_incontextgauss_ISR_A676881824 gale_healthsolutions_A676881824 crossref_primary_10_1038_s41577_021_00592_1 pubmed_primary_34373623 springer_journals_10_1038_s41577_021_00592_1
PublicationCentury	2000
PublicationDate	2021-10-01
PublicationDateYYYYMMDD	2021-10-01
PublicationDate_xml	– month: 10 year: 2021 text: 2021-10-01 day: 01
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Nature reviews. Immunology
PublicationTitleAbbrev	Nat Rev Immunol
PublicationTitleAlternate	Nat Rev Immunol
PublicationYear	2021
Publisher	Nature Publishing Group UK Nature Publishing Group
Publisher_xml	– name: Nature Publishing Group UK – name: Nature Publishing Group
References	Levine-Tiefenbrun (CR27) 2021; 27 Pimenta, Yates, Pagel, Gurdasani (CR22) 2021; 372 Duerr (CR94) 2012; 206 Lee (CR82) 2021 Voysey (CR4) 2021; 397 Wu (CR43) 2021 Ledford (CR51) 2021 Mallapaty (CR54) 2021 Hall (CR21) 2021; 397 Wang (CR48) 2021 De Faria (CR72) 2021 Shay (CR81) 2021; 70 Madhi (CR70) 2021 CR79 Campbell (CR69) 2021; 26 Gupta (CR39) 2021; 21 Abu-Raddad, Chemaitelly, Butt (CR67) 2021 Mathieu (CR1) 2021 Khoury (CR36) 2021 CR75 CR74 Vasileiou (CR24) 2021; 397 Mahase (CR65) 2021; 372 Callaway, Mallapaty (CR46) 2021; 590 Graham (CR66) 2021; 6 Voysey (CR52) 2021; 397 Wu (CR57) 2021 Faria (CR71) 2021; 372 Wang (CR61) 2021 Wang (CR47) 2021; 592 Kawasuji (CR93) 2020; 15 Tenforde (CR31) 2021; 70 CR5 CR8 CR9 Emary (CR44) 2021; 397 Shaw (CR76) 2021; 397 Greinacher (CR91) 2021 CR88 Dolgin (CR15) 2021; 594 Shimabukuro, Cole, Su (CR77) 2021; 325 Scully (CR86) 2021 CR40 Sheikh, McMenamin, Taylor, Robertson (CR56) 2021; 397 Baden (CR3) 2021; 384 CR80 Logunov (CR6) 2021; 397 Polack (CR2) 2020; 383 Othman, Labelle, Mazzetti, Elbatarny, Lillicrap (CR90) 2007; 109 Muik (CR42) 2021; 371 Sadoff (CR45) 2021; 384 Earle (CR18) 2021 Choi (CR59) 2011; 18 Wu (CR68) 2021; 384 Jin, Li, Pan, Wu, Zhu (CR35) 2021; 6 CR19 Bouton (CR29) 2021 Moghadas (CR34) 2021; 19 Wei (CR23) 2021 CR16 Swift (CR32) 2021 Greinacher (CR89) 2021 CR14 Bernal (CR20) 2021; 373 CR13 CR12 Greinacher (CR85) 2021 CR11 CR10 Noori (CR58) 2021 Parry (CR25) 2021 Thompson (CR30) 2021; 70 Kim, Marks, Clemens (CR7) 2021; 27 Wall (CR55) 2021; 397 Mahase (CR26) 2021; 372 Xie (CR41) 2021; 27 Ho (CR49) 2021 Pottegård (CR83) 2021; 373 Devasagayam, Wyatt, Leyden, Kleinig (CR92) 2016; 47 Jara (CR33) 2021 McDonald, Murray, Reynolds, Altmann, Boyton (CR17) 2021; 6 Turner (CR60) 2021 Chan (CR84) 2021 Larson (CR78) 2021 Reilly (CR87) 2003; 16 Huang (CR38) 2020; 11 Shilo, Rossman, Segal (CR28) 2021; 21 CR64 Wibmer (CR50) 2021; 27 Lazarus (CR63) 2020; 25 Feng (CR37) 2021 Tomic (CR62) 2021 Liu (CR53) 2021 Liu (CR73) 2021 S Shilo (592_CR28) 2021; 21 RK Gupta (592_CR39) 2021; 21 M Voysey (592_CR52) 2021; 397 M Levine-Tiefenbrun (592_CR27) 2021; 27 E De Faria (592_CR72) 2021 J Liu (592_CR73) 2021 A Duerr (592_CR94) 2012; 206 K Wu (592_CR68) 2021; 384 592_CR75 A Tomic (592_CR62) 2021 592_CR74 A Greinacher (592_CR89) 2021 H Kawasuji (592_CR93) 2020; 15 MS Graham (592_CR66) 2021; 6 A Jara (592_CR33) 2021 E Vasileiou (592_CR24) 2021; 397 M Noori (592_CR58) 2021 SA Madhi (592_CR70) 2021 JH Kim (592_CR7) 2021; 27 RH Shaw (592_CR76) 2021; 397 BT Chan (592_CR84) 2021 H Parry (592_CR25) 2021 592_CR9 592_CR8 E Callaway (592_CR46) 2021; 590 I McDonald (592_CR17) 2021; 6 K Wu (592_CR43) 2021 Z Wang (592_CR47) 2021; 592 VJ Hall (592_CR21) 2021; 397 YS Choi (592_CR59) 2011; 18 FP Polack (592_CR2) 2020; 383 S Feng (592_CR37) 2021 S Devasagayam (592_CR92) 2016; 47 592_CR79 A Pottegård (592_CR83) 2021; 373 592_CR5 M Scully (592_CR86) 2021 MW Tenforde (592_CR31) 2021; 70 592_CR40 S Mallapaty (592_CR54) 2021 M Voysey (592_CR4) 2021; 397 AT Huang (592_CR38) 2020; 11 EC Wall (592_CR55) 2021; 397 592_CR80 MD Swift (592_CR32) 2021 EJ Lee (592_CR82) 2021 Y Liu (592_CR53) 2021 MG Thompson (592_CR30) 2021; 70 D Ho (592_CR49) 2021 DK Shay (592_CR81) 2021; 70 JL Bernal (592_CR20) 2021; 373 X Xie (592_CR41) 2021; 27 M Othman (592_CR90) 2007; 109 A Muik (592_CR42) 2021; 371 H Ledford (592_CR51) 2021 F Campbell (592_CR69) 2021; 26 D Pimenta (592_CR22) 2021; 372 KRW Emary (592_CR44) 2021; 397 LR Baden (592_CR3) 2021; 384 592_CR88 J Wei (592_CR23) 2021 JV Lazarus (592_CR63) 2020; 25 DY Logunov (592_CR6) 2021; 397 592_CR10 RF Reilly (592_CR87) 2003; 16 J Sadoff (592_CR45) 2021; 384 K Wu (592_CR57) 2021 A Greinacher (592_CR91) 2021 TC Bouton (592_CR29) 2021 P Jin (592_CR35) 2021; 6 NR Faria (592_CR71) 2021; 372 E Mathieu (592_CR1) 2021 E Mahase (592_CR26) 2021; 372 LJ Abu-Raddad (592_CR67) 2021 592_CR19 A Greinacher (592_CR85) 2021 DS Khoury (592_CR36) 2021 P Wang (592_CR48) 2021 Z Wang (592_CR61) 2021 592_CR16 592_CR13 592_CR14 JS Turner (592_CR60) 2021 592_CR11 592_CR12 592_CR64 TT Shimabukuro (592_CR77) 2021; 325 CK Wibmer (592_CR50) 2021; 27 A Sheikh (592_CR56) 2021; 397 E Dolgin (592_CR15) 2021; 594 SM Moghadas (592_CR34) 2021; 19 E Mahase (592_CR65) 2021; 372 KA Earle (592_CR18) 2021 KF Larson (592_CR78) 2021
References_xml	– year: 2021 ident: CR1 article-title: A global database of COVID-19 vaccinations publication-title: Nat. Hum. Behav. doi: 10.1038/s41562-021-01122-8 contributor: fullname: Mathieu – year: 2021 ident: CR86 article-title: Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2105385 contributor: fullname: Scully – ident: CR74 – volume: 70 start-page: 495 year: 2021 end-page: 500 ident: CR30 article-title: Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers — eight U.S. locations, December 2020–March 2021 publication-title: MMWR contributor: fullname: Thompson – year: 2021 ident: CR25 article-title: Extended interval BNT162b2 vaccination enhances peak antibody generation in older people. Preprint at publication-title: medRxiv doi: 10.1101/2021.05.15.21257017 contributor: fullname: Parry – volume: 397 start-page: 1351 year: 2021 end-page: 1362 ident: CR44 article-title: Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(21)00628-0 contributor: fullname: Emary – ident: CR16 – ident: CR12 – volume: 372 start-page: n710 year: 2021 ident: CR22 article-title: Delaying the second dose of covid-19 vaccines publication-title: BMJ doi: 10.1136/bmj.n710 contributor: fullname: Gurdasani – volume: 372 start-page: n296 year: 2021 ident: CR65 article-title: Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant publication-title: BMJ doi: 10.1136/bmj.n296 contributor: fullname: Mahase – volume: 70 start-page: 674 year: 2021 end-page: 679 ident: CR31 article-title: Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged ≥65 years — United States, January–March 2021 publication-title: MMWR contributor: fullname: Tenforde – year: 2021 ident: CR78 article-title: Myocarditis after BNT162b2 and mRNA-1273 vaccination publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.121.055913 contributor: fullname: Larson – ident: CR80 – volume: 21 start-page: 198 year: 2021 end-page: 199 ident: CR28 article-title: Signals of hope: gauging the impact of a rapid national vaccination campaign publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-021-00531-0 contributor: fullname: Segal – ident: CR8 – year: 2021 ident: CR67 article-title: Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 Variants publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2104974 contributor: fullname: Butt – year: 2021 ident: CR62 article-title: Divergent trajectories of antiviral memory after SARS-Cov-2 infection publication-title: Rs. Sq. doi: 10.21203/RS.3.RS-612205/V1 contributor: fullname: Tomic – year: 2021 ident: CR89 article-title: Towards understanding ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) publication-title: Rs Sq. doi: 10.21203/rs.3.rs-440461/v1 contributor: fullname: Greinacher – volume: 27 start-page: 620 year: 2021 end-page: 621 ident: CR41 article-title: Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera publication-title: Nat. Med. doi: 10.1038/s41591-021-01270-4 contributor: fullname: Xie – volume: 27 start-page: 622 year: 2021 end-page: 625 ident: CR50 article-title: SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma publication-title: Nat. Med. doi: 10.1038/s41591-021-01285-x contributor: fullname: Wibmer – year: 2021 ident: CR58 article-title: “Original antigenic sin”: a potential threat beyond the development of booster vaccination against novel SARS-CoV-2 variants publication-title: Infect. Control. Hospital Epidemiol. doi: 10.1017/ice.2021.199 contributor: fullname: Noori – ident: CR19 – volume: 594 start-page: 483 year: 2021 end-page: 483 ident: CR15 article-title: CureVac COVID vaccine let-down spotlights mRNA design challenges publication-title: Nature doi: 10.1038/d41586-021-01661-0 contributor: fullname: Dolgin – volume: 16 start-page: 54 year: 2003 end-page: 60 ident: CR87 article-title: Heparin-induced thrombocytopenia in dialysis: the pathophysiology of immune-mediated heparin-induced thrombocytopenia publication-title: Semin. Dial. doi: 10.1046/j.1525-139X.2003.03013.x contributor: fullname: Reilly – volume: 372 start-page: 815 year: 2021 end-page: 821 ident: CR71 article-title: Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil publication-title: Science doi: 10.1126/science.abh2644 contributor: fullname: Faria – volume: 325 start-page: 1101 year: 2021 end-page: 1102 ident: CR77 article-title: Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021 publication-title: JAMA doi: 10.1001/jama.2021.1967 contributor: fullname: Su – volume: 27 start-page: 205 year: 2021 end-page: 211 ident: CR7 article-title: Looking beyond COVID-19 vaccine phase 3 trials publication-title: Nat. Med. doi: 10.1038/s41591-021-01230-y contributor: fullname: Clemens – ident: CR75 – year: 2021 ident: CR37 article-title: Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Preprint at publication-title: medRxiv doi: 10.1101/2021.06.21.21258528 contributor: fullname: Feng – year: 2021 ident: CR70 article-title: Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant publication-title: N. Engl. J. Med. doi: 10.1056/nejmoa2102214 contributor: fullname: Madhi – ident: CR88 – year: 2021 ident: CR32 article-title: Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciab361 contributor: fullname: Swift – ident: CR11 – ident: CR9 – volume: 371 start-page: 1152 year: 2021 end-page: 1153 ident: CR42 article-title: Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera publication-title: Science doi: 10.1126/science.abg6105 contributor: fullname: Muik – volume: 397 start-page: 2461 year: 2021 end-page: 2462 ident: CR56 article-title: SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness publication-title: Lancet doi: 10.1016/S0140-6736(21)01358-1 contributor: fullname: Robertson – volume: 384 start-page: 2187 year: 2021 end-page: 2201 ident: CR45 article-title: Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2101544 contributor: fullname: Sadoff – ident: CR5 – volume: 19 year: 2021 ident: CR34 article-title: Evaluation of COVID-19 vaccination strategies with a delayed second dose publication-title: PLoS Biol. doi: 10.1371/journal.pbio.3001211 contributor: fullname: Moghadas – volume: 21 start-page: 340 year: 2021 end-page: 341 ident: CR39 article-title: Will SARS-CoV-2 variants of concern affect the promise of vaccines? publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-021-00556-5 contributor: fullname: Gupta – volume: 592 start-page: 616 year: 2021 end-page: 622 ident: CR47 article-title: mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants publication-title: Nature doi: 10.1038/s41586-021-03324-6 contributor: fullname: Wang – year: 2021 ident: CR84 article-title: Meta-analysis of risk of vaccine-induced immune thrombotic thrombocytopenia following ChAdOx1-S recombinant vaccine. Preprint at publication-title: medRxiv doi: 10.1101/2021.05.04.21256613 contributor: fullname: Chan – ident: CR64 – volume: 373 start-page: n1114 year: 2021 ident: CR83 article-title: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Population based cohort study publication-title: BMJ doi: 10.1136/bmj.n1114 contributor: fullname: Pottegård – year: 2021 ident: CR60 article-title: SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans publication-title: Nature doi: 10.1038/s41586-021-03647-4 contributor: fullname: Turner – volume: 397 start-page: 1646 year: 2021 end-page: 1657 ident: CR24 article-title: Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study publication-title: Lancet doi: 10.1016/S0140-6736(21)00677-2 contributor: fullname: Vasileiou – volume: 397 start-page: 99 year: 2021 end-page: 111 ident: CR52 article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK publication-title: Lancet doi: 10.1016/S0140-6736(20)32661-1 contributor: fullname: Voysey – volume: 397 start-page: 2331 year: 2021 end-page: 2333 ident: CR55 article-title: Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination publication-title: Lancet doi: 10.1016/S0140-6736(21)01290-3 contributor: fullname: Wall – volume: 373 start-page: n1088 year: 2021 ident: CR20 article-title: Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study publication-title: BMJ doi: 10.1136/bmj.n1088 contributor: fullname: Bernal – year: 2021 ident: CR85 article-title: Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2104840 contributor: fullname: Greinacher – volume: 383 start-page: 2603 year: 2020 end-page: 2615 ident: CR2 article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2034577 contributor: fullname: Polack – volume: 6 start-page: e335 year: 2021 end-page: e345 ident: CR66 article-title: Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study publication-title: Lancet Public Heal. doi: 10.1016/S2468-2667(21)00055-4 contributor: fullname: Graham – volume: 70 start-page: 680 year: 2021 end-page: 684 ident: CR81 article-title: Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine - United States, March-April 2021 publication-title: MMWR contributor: fullname: Shay – ident: CR14 – volume: 590 start-page: 17 year: 2021 ident: CR46 article-title: Novavax offers first evidence that COVID vaccines protect people against variants publication-title: Nature doi: 10.1038/d41586-021-00268-9 contributor: fullname: Mallapaty – volume: 18 start-page: 1519 year: 2011 end-page: 1523 ident: CR59 article-title: Reduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccination publication-title: Clin. Vaccine Immunol. doi: 10.1128/CVI.05053-11 contributor: fullname: Choi – volume: 206 start-page: 258 year: 2012 end-page: 266 ident: CR94 article-title: Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study) publication-title: J. Infect. Dis. doi: 10.1093/infdis/jis342 contributor: fullname: Duerr – volume: 47 start-page: 2180 year: 2016 end-page: 2182 ident: CR92 article-title: Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study publication-title: Stroke doi: 10.1161/STROKEAHA.116.013617 contributor: fullname: Kleinig – ident: CR10 – year: 2021 ident: CR91 article-title: Anti-SARS-CoV-2 spike protein and anti-platelet factor 4 antibody responses induced by COVID-19 disease and ChAdOx1 nCov-19 vaccination publication-title: Research Square doi: 10.21203/rs.3.rs-404769/v1 contributor: fullname: Greinacher – volume: 15 year: 2020 ident: CR93 article-title: Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients publication-title: PLoS ONE doi: 10.1371/journal.pone.0243597 contributor: fullname: Kawasuji – year: 2021 ident: CR72 article-title: Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) — preliminary report. Preprint at publication-title: medRxiv doi: 10.1101/2021.04.12.21255308 contributor: fullname: De Faria – year: 2021 ident: CR54 article-title: China COVID vaccine reports mixed results — what does that mean for the pandemic? publication-title: Nature doi: 10.1038/d41586-021-00094-z contributor: fullname: Mallapaty – year: 2021 ident: CR57 article-title: Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Preprint at publication-title: bioRxiv doi: 10.1101/2021.04.13.439482 contributor: fullname: Wu – ident: CR79 – volume: 397 start-page: 1725 year: 2021 end-page: 1735 ident: CR21 article-title: COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study publication-title: Lancet doi: 10.1016/S0140-6736(21)00790-X contributor: fullname: Hall – year: 2021 ident: CR33 article-title: Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2107715 contributor: fullname: Jara – volume: 384 start-page: 1468 year: 2021 end-page: 1470 ident: CR68 article-title: Serum neutralizing activity elicited by mRNA-1273 vaccine publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2102179 contributor: fullname: Wu – year: 2021 ident: CR48 article-title: Antibody resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 publication-title: Nature doi: 10.1038/s41586-021-03398-2 contributor: fullname: Wang – year: 2021 ident: CR29 article-title: COVID-19 vaccine impact on rates of SARS-CoV-2 cases and post vaccination strain sequences among healthcare workers at an urban academic medical center: a prospective cohort study. Preprint at publication-title: medRxiv doi: 10.1101/2021.03.30.21254655 contributor: fullname: Bouton – ident: CR40 – year: 2021 ident: CR73 article-title: BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants publication-title: Nature doi: 10.1038/s41586-021-03693-y contributor: fullname: Liu – volume: 384 start-page: 403 year: 2021 end-page: 416 ident: CR3 article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2035389 contributor: fullname: Baden – year: 2021 ident: CR18 article-title: Evidence for antibody as a protective correlate for COVID-19 vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2021.05.063 contributor: fullname: Earle – volume: 11 start-page: 1 year: 2020 end-page: 16 ident: CR38 article-title: A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity publication-title: Nat. Commun. doi: 10.1038/s41467-020-18450-4 contributor: fullname: Huang – volume: 397 start-page: 2043 year: 2021 end-page: 2046 ident: CR76 article-title: Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data publication-title: Lancet doi: 10.1016/S0140-6736(21)01115-6 contributor: fullname: Shaw – volume: 27 start-page: 198 year: 2021 end-page: 199 ident: CR27 article-title: Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine publication-title: Nat. Med. contributor: fullname: Levine-Tiefenbrun – year: 2021 ident: CR36 article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection publication-title: Nat. Med. doi: 10.1038/s41591-021-01377-8. contributor: fullname: Khoury – volume: 6 start-page: 1 year: 2021 end-page: 14 ident: CR17 article-title: Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2 publication-title: NPJ Vaccines doi: 10.1038/s41541-021-00336-1 contributor: fullname: Boyton – volume: 6 start-page: 1 year: 2021 end-page: 6 ident: CR35 article-title: Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need publication-title: Signal. Transduct. Target. Ther. contributor: fullname: Zhu – year: 2021 ident: CR53 article-title: Neutralizing activity of BNT162b2-elicited serum publication-title: N. Engl. J. Med. doi: 10.1056/nejmc2102017 contributor: fullname: Liu – volume: 397 start-page: 881 year: 2021 end-page: 891 ident: CR4 article-title: Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials publication-title: Lancet doi: 10.1016/S0140-6736(21)00432-3 contributor: fullname: Voysey – year: 2021 ident: CR23 article-title: The impact of SARS-CoV-2 vaccines on antibody responses in the general population in the United Kingdom. Preprint at publication-title: medRxiv doi: 10.1101/2021.04.22.21255911 contributor: fullname: Wei – volume: 372 start-page: n338 year: 2021 ident: CR26 article-title: Covid-19: Israel sees new infections plummet following vaccinations publication-title: BMJ doi: 10.1136/bmj.n338 contributor: fullname: Mahase – year: 2021 ident: CR61 article-title: Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection publication-title: Nature doi: 10.1038/s41586-021-03696-9 contributor: fullname: Wang – ident: CR13 – volume: 397 start-page: 671 year: 2021 end-page: 681 ident: CR6 article-title: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia publication-title: Lancet doi: 10.1016/S0140-6736(21)00234-8 contributor: fullname: Logunov – year: 2021 ident: CR82 article-title: Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination publication-title: Am. J. Hematol. doi: 10.1002/ajh.26132 contributor: fullname: Lee – volume: 25 start-page: 799 year: 2020 end-page: 807 ident: CR63 article-title: Hesitant or not? The association of age, gender, and education with potential acceptance of a COVID-19 vaccine: a country-level analysis publication-title: J. Health Commun. doi: 10.1080/10810730.2020.1868630 contributor: fullname: Lazarus – year: 2021 ident: CR43 article-title: mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. Preprint at publication-title: bioRxiv doi: 10.1101/2021.01.25.427948 contributor: fullname: Wu – year: 2021 ident: CR51 article-title: J&J’s one-shot COVID vaccine offers hope for faster protection publication-title: Nature doi: 10.1038/d41586-021-00119-7. contributor: fullname: Ledford – volume: 26 start-page: 2100509 year: 2021 ident: CR69 article-title: Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021 publication-title: Euro Surveill. doi: 10.2807/1560-7917.ES.2021.26.24.2100509 contributor: fullname: Campbell – volume: 109 start-page: 2832 year: 2007 end-page: 2839 ident: CR90 article-title: Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance publication-title: Blood doi: 10.1182/blood-2006-06-032524 contributor: fullname: Lillicrap – year: 2021 ident: CR49 article-title: Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization publication-title: Res. Sq. doi: 10.21203/rs.3.rs-155394/v1 contributor: fullname: Ho – volume: 27 start-page: 205 year: 2021 ident: 592_CR7 publication-title: Nat. Med. doi: 10.1038/s41591-021-01230-y contributor: fullname: JH Kim – volume: 11 start-page: 1 year: 2020 ident: 592_CR38 publication-title: Nat. Commun. doi: 10.1038/s41467-020-18450-4 contributor: fullname: AT Huang – year: 2021 ident: 592_CR58 publication-title: Infect. Control. Hospital Epidemiol. doi: 10.1017/ice.2021.199 contributor: fullname: M Noori – year: 2021 ident: 592_CR54 publication-title: Nature doi: 10.1038/d41586-021-00094-z contributor: fullname: S Mallapaty – ident: 592_CR10 – volume: 397 start-page: 2043 year: 2021 ident: 592_CR76 publication-title: Lancet doi: 10.1016/S0140-6736(21)01115-6 contributor: fullname: RH Shaw – ident: 592_CR14 – year: 2021 ident: 592_CR37 publication-title: medRxiv doi: 10.1101/2021.06.21.21258528 contributor: fullname: S Feng – year: 2021 ident: 592_CR78 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.121.055913 contributor: fullname: KF Larson – year: 2021 ident: 592_CR73 publication-title: Nature doi: 10.1038/s41586-021-03693-y contributor: fullname: J Liu – year: 2021 ident: 592_CR82 publication-title: Am. J. Hematol. doi: 10.1002/ajh.26132 contributor: fullname: EJ Lee – volume: 27 start-page: 622 year: 2021 ident: 592_CR50 publication-title: Nat. Med. doi: 10.1038/s41591-021-01285-x contributor: fullname: CK Wibmer – volume: 6 start-page: 1 year: 2021 ident: 592_CR35 publication-title: Signal. Transduct. Target. Ther. doi: 10.1038/s41392-020-00451-w contributor: fullname: P Jin – volume: 25 start-page: 799 year: 2020 ident: 592_CR63 publication-title: J. Health Commun. doi: 10.1080/10810730.2020.1868630 contributor: fullname: JV Lazarus – volume: 206 start-page: 258 year: 2012 ident: 592_CR94 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jis342 contributor: fullname: A Duerr – year: 2021 ident: 592_CR61 publication-title: Nature doi: 10.1038/s41586-021-03696-9 contributor: fullname: Z Wang – volume: 6 start-page: e335 year: 2021 ident: 592_CR66 publication-title: Lancet Public Heal. doi: 10.1016/S2468-2667(21)00055-4 contributor: fullname: MS Graham – year: 2021 ident: 592_CR72 publication-title: medRxiv doi: 10.1101/2021.04.12.21255308 contributor: fullname: E De Faria – ident: 592_CR19 – year: 2021 ident: 592_CR36 publication-title: Nat. Med. doi: 10.1038/s41591-021-01377-8. contributor: fullname: DS Khoury – volume: 21 start-page: 198 year: 2021 ident: 592_CR28 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-021-00531-0 contributor: fullname: S Shilo – ident: 592_CR88 – volume: 373 start-page: n1088 year: 2021 ident: 592_CR20 publication-title: BMJ doi: 10.1136/bmj.n1088 contributor: fullname: JL Bernal – volume: 397 start-page: 2331 year: 2021 ident: 592_CR55 publication-title: Lancet doi: 10.1016/S0140-6736(21)01290-3 contributor: fullname: EC Wall – volume: 594 start-page: 483 year: 2021 ident: 592_CR15 publication-title: Nature doi: 10.1038/d41586-021-01661-0 contributor: fullname: E Dolgin – volume: 70 start-page: 680 year: 2021 ident: 592_CR81 publication-title: MMWR contributor: fullname: DK Shay – volume: 384 start-page: 2187 year: 2021 ident: 592_CR45 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2101544 contributor: fullname: J Sadoff – volume: 397 start-page: 99 year: 2021 ident: 592_CR52 publication-title: Lancet doi: 10.1016/S0140-6736(20)32661-1 contributor: fullname: M Voysey – ident: 592_CR11 – ident: 592_CR80 – volume: 383 start-page: 2603 year: 2020 ident: 592_CR2 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2034577 contributor: fullname: FP Polack – year: 2021 ident: 592_CR51 publication-title: Nature doi: 10.1038/d41586-021-00119-7. contributor: fullname: H Ledford – volume: 384 start-page: 403 year: 2021 ident: 592_CR3 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2035389 contributor: fullname: LR Baden – volume: 397 start-page: 2461 year: 2021 ident: 592_CR56 publication-title: Lancet doi: 10.1016/S0140-6736(21)01358-1 contributor: fullname: A Sheikh – volume: 47 start-page: 2180 year: 2016 ident: 592_CR92 publication-title: Stroke doi: 10.1161/STROKEAHA.116.013617 contributor: fullname: S Devasagayam – volume: 397 start-page: 881 year: 2021 ident: 592_CR4 publication-title: Lancet doi: 10.1016/S0140-6736(21)00432-3 contributor: fullname: M Voysey – volume: 371 start-page: 1152 year: 2021 ident: 592_CR42 publication-title: Science doi: 10.1126/science.abg6105 contributor: fullname: A Muik – volume: 21 start-page: 340 year: 2021 ident: 592_CR39 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-021-00556-5 contributor: fullname: RK Gupta – volume: 325 start-page: 1101 year: 2021 ident: 592_CR77 publication-title: JAMA doi: 10.1001/jama.2021.1967 contributor: fullname: TT Shimabukuro – year: 2021 ident: 592_CR32 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciab361 contributor: fullname: MD Swift – year: 2021 ident: 592_CR86 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2105385 contributor: fullname: M Scully – volume: 590 start-page: 17 year: 2021 ident: 592_CR46 publication-title: Nature doi: 10.1038/d41586-021-00268-9 contributor: fullname: E Callaway – ident: 592_CR64 – year: 2021 ident: 592_CR25 publication-title: medRxiv doi: 10.1101/2021.05.15.21257017 contributor: fullname: H Parry – year: 2021 ident: 592_CR33 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2107715 contributor: fullname: A Jara – ident: 592_CR74 – volume: 70 start-page: 495 year: 2021 ident: 592_CR30 publication-title: MMWR contributor: fullname: MG Thompson – year: 2021 ident: 592_CR70 publication-title: N. Engl. J. Med. doi: 10.1056/nejmoa2102214 contributor: fullname: SA Madhi – year: 2021 ident: 592_CR85 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2104840 contributor: fullname: A Greinacher – ident: 592_CR16 – volume: 397 start-page: 1725 year: 2021 ident: 592_CR21 publication-title: Lancet doi: 10.1016/S0140-6736(21)00790-X contributor: fullname: VJ Hall – ident: 592_CR8 – volume: 27 start-page: 620 year: 2021 ident: 592_CR41 publication-title: Nat. Med. doi: 10.1038/s41591-021-01270-4 contributor: fullname: X Xie – ident: 592_CR12 – year: 2021 ident: 592_CR1 publication-title: Nat. Hum. Behav. doi: 10.1038/s41562-021-01122-8 contributor: fullname: E Mathieu – ident: 592_CR5 – volume: 592 start-page: 616 year: 2021 ident: 592_CR47 publication-title: Nature doi: 10.1038/s41586-021-03324-6 contributor: fullname: Z Wang – year: 2021 ident: 592_CR23 publication-title: medRxiv doi: 10.1101/2021.04.22.21255911 contributor: fullname: J Wei – year: 2021 ident: 592_CR53 publication-title: N. Engl. J. Med. doi: 10.1056/nejmc2102017 contributor: fullname: Y Liu – volume: 373 start-page: n1114 year: 2021 ident: 592_CR83 publication-title: BMJ doi: 10.1136/bmj.n1114 contributor: fullname: A Pottegård – year: 2021 ident: 592_CR67 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2104974 contributor: fullname: LJ Abu-Raddad – volume: 372 start-page: n338 year: 2021 ident: 592_CR26 publication-title: BMJ doi: 10.1136/bmj.n338 contributor: fullname: E Mahase – year: 2021 ident: 592_CR84 publication-title: medRxiv doi: 10.1101/2021.05.04.21256613 contributor: fullname: BT Chan – volume: 372 start-page: 815 year: 2021 ident: 592_CR71 publication-title: Science doi: 10.1126/science.abh2644 contributor: fullname: NR Faria – volume: 397 start-page: 1646 year: 2021 ident: 592_CR24 publication-title: Lancet doi: 10.1016/S0140-6736(21)00677-2 contributor: fullname: E Vasileiou – volume: 26 start-page: 2100509 year: 2021 ident: 592_CR69 publication-title: Euro Surveill. doi: 10.2807/1560-7917.ES.2021.26.24.2100509 contributor: fullname: F Campbell – year: 2021 ident: 592_CR48 publication-title: Nature doi: 10.1038/s41586-021-03398-2 contributor: fullname: P Wang – volume: 384 start-page: 1468 year: 2021 ident: 592_CR68 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2102179 contributor: fullname: K Wu – year: 2021 ident: 592_CR62 publication-title: Rs. Sq. doi: 10.21203/RS.3.RS-612205/V1 contributor: fullname: A Tomic – year: 2021 ident: 592_CR60 publication-title: Nature doi: 10.1038/s41586-021-03647-4 contributor: fullname: JS Turner – volume: 109 start-page: 2832 year: 2007 ident: 592_CR90 publication-title: Blood doi: 10.1182/blood-2006-06-032524 contributor: fullname: M Othman – volume: 397 start-page: 671 year: 2021 ident: 592_CR6 publication-title: Lancet doi: 10.1016/S0140-6736(21)00234-8 contributor: fullname: DY Logunov – volume: 70 start-page: 674 year: 2021 ident: 592_CR31 publication-title: MMWR contributor: fullname: MW Tenforde – volume: 18 start-page: 1519 year: 2011 ident: 592_CR59 publication-title: Clin. Vaccine Immunol. doi: 10.1128/CVI.05053-11 contributor: fullname: YS Choi – year: 2021 ident: 592_CR43 publication-title: bioRxiv doi: 10.1101/2021.01.25.427948 contributor: fullname: K Wu – volume: 27 start-page: 198 year: 2021 ident: 592_CR27 publication-title: Nat. Med. doi: 10.1038/s41591-021-01242-8 contributor: fullname: M Levine-Tiefenbrun – ident: 592_CR9 – year: 2021 ident: 592_CR18 publication-title: Vaccine doi: 10.1016/j.vaccine.2021.05.063 contributor: fullname: KA Earle – volume: 372 start-page: n296 year: 2021 ident: 592_CR65 publication-title: BMJ doi: 10.1136/bmj.n296 contributor: fullname: E Mahase – volume: 15 year: 2020 ident: 592_CR93 publication-title: PLoS ONE doi: 10.1371/journal.pone.0243597 contributor: fullname: H Kawasuji – year: 2021 ident: 592_CR89 publication-title: Rs Sq. doi: 10.21203/rs.3.rs-440461/v1 contributor: fullname: A Greinacher – year: 2021 ident: 592_CR57 publication-title: bioRxiv doi: 10.1101/2021.04.13.439482 contributor: fullname: K Wu – ident: 592_CR13 – ident: 592_CR79 – year: 2021 ident: 592_CR91 publication-title: Research Square doi: 10.21203/rs.3.rs-404769/v1 contributor: fullname: A Greinacher – year: 2021 ident: 592_CR29 publication-title: medRxiv doi: 10.1101/2021.03.30.21254655 contributor: fullname: TC Bouton – ident: 592_CR75 – volume: 372 start-page: n710 year: 2021 ident: 592_CR22 publication-title: BMJ doi: 10.1136/bmj.n710 contributor: fullname: D Pimenta – volume: 397 start-page: 1351 year: 2021 ident: 592_CR44 publication-title: Lancet doi: 10.1016/S0140-6736(21)00628-0 contributor: fullname: KRW Emary – ident: 592_CR40 – volume: 16 start-page: 54 year: 2003 ident: 592_CR87 publication-title: Semin. Dial. doi: 10.1046/j.1525-139X.2003.03013.x contributor: fullname: RF Reilly – volume: 19 year: 2021 ident: 592_CR34 publication-title: PLoS Biol. doi: 10.1371/journal.pbio.3001211 contributor: fullname: SM Moghadas – year: 2021 ident: 592_CR49 publication-title: Res. Sq. doi: 10.21203/rs.3.rs-155394/v1 contributor: fullname: D Ho – volume: 6 start-page: 1 year: 2021 ident: 592_CR17 publication-title: NPJ Vaccines doi: 10.1038/s41541-021-00336-1 contributor: fullname: I McDonald
SSID	ssj0016174
Score	2.7727563
SecondaryResourceType	review_article
Snippet	Where 2020 saw the development and testing of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first...
SourceID	pubmedcentral proquest gale crossref pubmed springer
SourceType	Open Access Repository Aggregation Database Index Database Publisher
StartPage	626
SubjectTerms	631/250/590 631/326/596/4130 Adverse and side effects Biomedical and Life Sciences Biomedicine Clinical Trials as Topic Control Coronaviruses COVID-19 COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - adverse effects COVID-19 Vaccines - classification COVID-19 Vaccines - immunology Drugs Epidemics Health Services Accessibility Humans Immunology Medical research Medicine, Experimental Pandemics Progress SARS-CoV-2 - classification SARS-CoV-2 - genetics SARS-CoV-2 - immunology Severe acute respiratory syndrome coronavirus 2 United Kingdom Vaccine efficacy Vaccines Viruses World Health Organization
Title	Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
URI	https://link.springer.com/article/10.1038/s41577-021-00592-1 https://www.ncbi.nlm.nih.gov/pubmed/34373623 https://www.proquest.com/docview/2576737735 https://pubmed.ncbi.nlm.nih.gov/PMC8351583
Volume	21
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELfYJhAvCMZXxigWQuKBWsuHEye8oLas2pBWpsFQ3yw7sdle0m1OJ-2_585JO1IJnprIF9XxnX2_y30R8iEVGrazSlmoioRxm6ZMaSFYaEGbaZsVKsVE4ZNZdnTOv83TeffBzXVhlasz0R_U1aLEb-QHCIxFIkSSfrm6Ztg1Cr2rXQuNLbIToaLDTPHJOsQDobv3KnPBWSSSpEuaCZP8wIHiwinFYEwDwohZ1FNMm8fzX_ppM3Zyw4Hq9dL0KXnSAUo6aiXgGXlg6l3ysG0xebdLHp10zvPn5PoUY7HgZKMLSwH30cn3X8dfWVTQW1UiCTUWIGzzmd5e3iydccPVgKOqruAGhLVuHMVIjqVDauBweTekbVBId256WuMwsOoFOZ8e_pwcsa7jAiszETcs04qXuTBxXIFdZ3SmVGUrQGUGYC1AoVBj_ymrdFFZuEw1GCeG8zLmJse75CXZrhe1eU0oz6xWlSl1XoCJA0Z4oawqranyvDKhrQLyabXc8qotrCG9QzzJZcscCcyRnjkyCsg75Ihsk0PXu1KOMjCXAHPEPCDvPQXWtKgxaOa3Wjonj3-c9Yg-dkR2AdyDNWpzEGDKWAarR7nfo4RNV_aHV6Ihu03v5L2IBuRVKyXrV0uwhBRAzYCInvysCbDMd3-kvrzw5b4BI0dpDk8OV5J2_5f_XrG9_8_wDXkco_D7sMR9st3cLM1bgFeNHpAtMRcDv5MGZGc0HY9n8Ds-nJ2e_QEGNSW3
link.rule.ids	230,314,780,784,885,12056,12223,21388,27924,27925,31719,33266,33744,43310,43579,43805,73745,74014,74302
linkProvider	ProQuest
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgiI8XBOMrMJiFkHig1vLhxAkvaCpMLawDwYb2ZtmJve0l3eZ00v577hy3I5XgrZGvquv7-l3ufEfIu1xoUGeVs1hVGeM2z5nSQrDYgjfTtqhUjheFZwfF5Ih_Pc6Pwws3F8oqlzbRG-pmXuM78h0ExiITIss_nV8wnBqF2dUwQuM2uQNuX6BUl-NViQdCd59V5oKzRGRZuDQTZ-WOA8eFW0ohmAaEkbJk4JjWzfNf_mm9dnItger90t4j8jAASrrbS8Bjcsu0m-RuP2LyepPcm4Xk-RNy8QNrscCy0bmlgPvo-Pvv6WeWVPRK1UhCjQUI232kV2eXC2fcaLngqGobeABhbTtHsZJj4ZAaOFxfj2hfFBLspqc1DgurnpKjvS-H4wkLExdYXYi0Y4VWvC6FSdMG4jqjC6Ua2wAqMwBrAQrFGudPWaWrxsLHXENwYjivU25KfMqekY123poXhPLCatWYWpcVhDgQhFfKqtqapiwbE9smIh-Wxy3P-8Ya0ifEs1L2zJHAHOmZI5OIbCNHZH85dKWVcreAcAkwR8oj8tZTYE-LFotmTtTCOTn99XNA9D4Q2TlwD86ov4MAW8Y2WAPKrQElKF09XF6KhgxK7-SNiEbkeS8lq7-WYQspgJoREQP5WRFgm-_hSnt26tt9A0ZO8hK-OVpK2s1P_vvEXv5_h9vk_uRwti_3pwffXpEHKSqCL1HcIhvd5cK8BqjV6Tden_4A7QYktg
linkToPdf	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LbxMxELagiIoLgvLaUqiFkDgQK_v2LhdUpUQN0FIBRb1Z9tqmvWzaelOp_54Zr5OykeCWlSeK43l9szOeIeRtwRWosyxYLOuM5bYomFScs9iCN1O2rGWBF4UPj8qDk_zzaXEa6p9cKKtc2kRvqPW8wXfkYwTGPOM8K8Y2lEUc708_XlwynCCFmdYwTuMuuYdT5rCPfjVZlXsgjPcZ5pznLOFZFi7QxFk1duDEcHspBNaANlKWDJzUuqn-y1et11GuJVO9j5o-Ig8DuKR7vTQ8JndMu0Xu9-Mmb7bI5mFIpD8hl8dYlwVWjs4tBQxIJ99-zfZZUtNr2SAJNRbgbPeBXp9fLZxxo-WCo7LV8ACC23aOYlXHwiE1cLu5GdG-QCTYUE9rHBZZPSUn008_JwcsTF9gTcnTjpVK5k3FTZpqiPGMKqXUVgNCMwBxARbFCmdRWalqbeFjoSBQMXnepLmp8Cl7RjbaeWteEJqXVkltGlXVEO5AQF5LKxtrdFVpE1sdkffL4xYXfZMN4ZPjWSV65ghgjvDMEUlEdpEjor8outJQsVdC6AT4I80j8sZTYH-LFiXlt1w4J2Y_vg-I3gUiOwfuwRn19xFgy9gSa0C5M6AEBWyGy0vREMEAOHErrhF53kvJ6q9l2E4KYGdE-EB-VgTY8nu40p6f-dbfgJeTooJvjpaSdvuT_z6x7f_vcJdsgiqJr7OjLy_JgxT1wFcr7pCN7mphXgHq6tRrr05_AK2mKNs
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Progress+of+the+COVID-19+vaccine+effort%3A+viruses%2C+vaccines+and+variants+versus+efficacy%2C+effectiveness+and+escape&rft.jtitle=Nature+reviews.+Immunology&rft.au=Tregoning%2C+John+S&rft.au=Flight%2C+Katie+E&rft.au=Higham%2C+Sophie+L&rft.au=Wang%2C+Ziyin&rft.date=2021-10-01&rft.pub=Nature+Publishing+Group&rft.issn=1474-1733&rft.volume=21&rft.issue=10&rft.spage=626&rft_id=info:doi/10.1038%2Fs41577-021-00592-1&rft.externalDocID=A676881824
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1474-1733&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1474-1733&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1474-1733&client=summon